[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"low-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:low-rectal-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100628563","results-of-low-anterior-resections-with-or-without-preventive-stoma-in-nonemergency-department-100628563",false,"NCT07463261","REsults of LOw Anterior Resections With or Without Preventive Stoma in Nonemergency Department","Results of Anastomotic Leak After Low Anterior Resection With or Without Preventive Stoma for Rectal Cancer in Low-risk Patients in Nonemergency Departments (RELOAD): Protocol of Multicenter Randomized Controlled Non-inferiority Trial","RELOAD","Inclusion Criteria:\n\n* Age \\>18 years;\n* Primary rectal cancer staged as cT1-4aN0-3M0 (or ycT0-4aN0-2M0);\n* Histologically confirmed rectal adenocarcinoma based on endoscopic biopsy;\n* Tumor located ≤12 cm from the dentate line (based on endoscopy, digital rectal examination, and\u002For pelvic MRI);\n* Planned radical minimally invasive (laparoscopic\u002Frobot-assisted) intervention with TME and formation of primary colorectal\u002Fcolonanal anastomosis;\n* Adequate hematologic function: hemoglobin ≥100 g\u002FL, leukocytes \\>4 × 10\\^9\u002FL, platelets \\>100 × 10\\^9\u002FL;\n* Adequate renal function: serum creatinine \\\u003C150 µmol\u002FL;\n* Adequate hepatic function: AST\u002FALT \\\u003C100 U\u002FL;\n* Predicted risk of anastomotic leakage ≤10% (AFOR 0-1).\n\nExclusion Criteria:\n\n* Age ≥80 years;\n* Presence of a pre-existing diverting ileostomy or colostomy;\n* Peritumoral abscess or tumor perforation;\n* Distant metastases (M1) identified preoperatively and\u002For intraoperatively;\n* Synchronous or metachronous malignancy;\n* Prior pelvic irradiation for another condition (e.g., cervical or prostate cancer);\n* Evidence of malnutrition (serum albumin \\\u003C34 g\u002FL);\n* Severe uncontrolled comorbid conditions (e.g., acute myocardial infarction, uncontrolled hypertension, decompensated heart failure, immunosuppression, systemic corticosteroid therapy, severe chronic obstructive pulmonary disease, chronic kidney disease stage 4-5), type 1 or type 2 diabetes mellitus, or psychiatric\u002Fneurological disorders impairing the ability to provide informed consent;\n* Tumor invasion into adjacent structures or organs (cT4b) identified preoperatively and\u002For intraoperatively;\n* Predicted risk of anastomotic leakage \\>10% (AFOR 2-6).","ALL","18 Years","70 Years",{"count":21,"type":22},442,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this multicenter randomized non-inferiority trial is to evaluate the safety of low anterior resection for rectal cancer performed with versus without a diverting stoma in patients with a low predicted risk of colorectal anastomotic leakage.\n\nThe primary objective is to determine whether the rate of anastomotic leakage within 30 days after surgery in the no-stoma group is non-inferior to that in the diverting stoma group.\n\nThe secondary objectives include comparison between groups regarding: Stoma rate at 1 year after surgery; Quality of life at 30 days and 1 year (EORTC QLQ-C30, EORTC QLQ-CR29, and LARS score); Short-term postoperative outcomes, including postoperative day metrics, length of hospital stay, and complications graded according to the Clavien-Dindo classification; Reoperation rates within 30 days and 1 year.\n\nParticipants will include adult patients with mid- or low-rectal adenocarcinoma who are scheduled for radical minimally invasive total mesorectal excision and have a predicted risk of anastomotic leakage \\\u003C10% according to the study risk model.",[28,29,30,31,32],"TME","Rectal Cancer Surgery","Low Rectal Cancer","Middle Rectal Cancer","Local Advanced Rectal Cancer",[34,35,36,37,38],"rectal cancer","preventive stoma","randomized trial","low-risk patients","anastomotic leak","RECRUITING","2026-05-11",{"date":42,"type":43},"2026-05-13","ACTUAL",{"date":45,"type":43},"2026-05-05",{"date":47,"type":22},"2027-06-10",{"name":49,"class":50},"ANO Scientific and Practical Club for the Development of Modern Medical Technologies","OTHER",7,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100513990","phase-2-nodes-sparing-short-course-radiation-combined-with-capox-and-tislelizumab-for-mss-middle-and-low-rectal-cancer-100513990","NCT05972655","Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer (mRCAT): An Open-label, Single-arm, Prospective Multicenter Clinical Trial","mRCAT","Inclusion Criteria:\n\n1. Patients who have a strong willingness to preserve the anus and are willing to receive neoadjuvant therapy.\n2. Male or Female aged 18-75.\n3. Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT2N+M0\u002FcT3-4aN0\u002F+M0, the lymph nodes are limited to the mesorectum, the circumferential resection margin is negative.\n4. Histologically confirmed rectal adenocarcinoma; Genetic testing suggests MSI-L or MSS, or tumor biopsy immunohistochemistry reveals pMMR, that is, MSH1, MSH2, MSH6, and PMS2 are all positive.\n5. Eastern Cooperative Oncology Group (ECOG) 0-1.\n6. No previous treatment(including anti-tumor therapy、immunotherapy or pelvic radiation).\n7. Adequate hematologic, hepatic, renal, thyroid and cardiac function: white blood cells ≥3500\u002Fmm3, neutrophils ≥1800\u002Fmm3, platelets ≥100,000\u002Fmm3, hemoglobin ≥100 g\u002FL; activated partial thromboplastin time, prothrombin time and international normalized ratio ≤1.5 × ULN; aspartate aminotransferase and alanine aminotransferase ≤3.0 × upper limit of normal (ULN), bilirubin ≤1.25 × ULN, serum albumin ≥28 g\u002FL. creatinine clearance ≥50 mL\u002Fmi, creatinine ≤1.5 × ULN;\n8. Informed consent form signed.\n\nExclusion Criteria:\n\n1. Patients with a previous history of malignant tumors besides rectal cancer.\n2. Patients with distant metastases before enrollment.\n3. Patients with positive internal or external iliac lymph nodes are assessed by MRI or CT.\n4. Patients with obstruction, perforation, or bleeding that require emergency surgery.\n5. Patients with severe concomitant diseases and estimated survival time ≤ 5 years.\n6. Allergic to any component of the therapy.\n7. Patients with poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous adenocarcinoma.\n8. Patients who received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of therapy.\n9. Patients who have received any other experimental drug (including immunotherapy) or participated in another interventional clinical trial within 30 days before screening.\n10. Factors leading to study termination, such as alcoholism, drug abuse, other serious illnesses (including psychiatric disorders) requiring combination therapy, and patients with severe laboratory abnormalities.\n11. Patients with congenital or acquired immune deficiency (such as HIV infection).\n12. Vulnerable groups, including mentally ill, cognitively impaired, critically ill patients, minors, pregnant or lactating women, illiterate, etc.\n13. Other conditions that investigators consider not suitable for this study.","75 Years",{"count":62,"type":22},32,[64],"PHASE2","This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tislelizumab) for patients with MSS middle and low rectal cancer. A total of 32 patients will be enrolled in this trial. The primary endpoint is the rate of pathological complete response (pCR). The organ preservation rate, tumor regression grade, long-term prognosis, and adverse effects will also be analyzed.",[30],"2025-01-07",{"date":69,"type":43},"2025-01-09",{"date":71,"type":43},"2023-08-02",{"date":73,"type":22},"2026-05-01",{"name":75,"class":50},"Sir Run Run Shaw Hospital",1]